cross-reactive antibody to non-human adenovirus vaccine vectors 2

[1]  A. Folgori,et al.  Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector , 2012, The Journal of infectious diseases.

[2]  A. Nicosia,et al.  Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. , 2009, Vaccine.

[3]  M. Betts,et al.  Adenovirus-Specific Immunity Following Immunization with an Ad5 HIV-1 Vaccine Candidate in Humans , 2009, Nature Medicine.

[4]  D. Metzgar,et al.  A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. , 2008, Vaccine.

[5]  J. Kublin,et al.  Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  N. Letvin,et al.  Effect of Preexisting Immunity to Adenovirus Human Serotype 5 Antigens on the Immune Responses of Nonhuman Primates to Vaccine Regimens Based on Human- or Chimpanzee-Derived Adenovirus Vectors , 2007, Journal of Virology.

[7]  J. Mascola,et al.  Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. , 2006, The Journal of infectious diseases.

[8]  A. Heim,et al.  Phylogenetic Analysis of the Main Neutralization and Hemagglutination Determinants of All Human Adenovirus Prototypes as a Basis for Molecular Classification and Taxonomy , 2005, Journal of Virology.

[9]  G. Nabel,et al.  Adenovirus vector-based vaccines for human immunodeficiency virus type 1. , 2005, Human gene therapy.

[10]  Hildegund C.J. Ertl,et al.  Adenoviruses as vaccine vectors , 2004, Molecular Therapy.

[11]  Jaap Goudsmit,et al.  Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors , 2003, Journal of Clinical Microbiology.

[12]  G. Gray,et al.  Large, persistent epidemic of adenovirus type 4-associated acute respiratory disease in U.S. army trainees. , 1999, Emerging infectious diseases.

[13]  J. Gaydos,et al.  Reemergence of adenovirus type 4 acute respiratory disease in military trainees: report of an outbreak during a lapse in vaccination. , 1999, The Journal of infectious diseases.

[14]  J. Gall,et al.  Construction and Characterization of Hexon-Chimeric Adenoviruses: Specification of Adenovirus Serotype , 1998, Journal of Virology.

[15]  R. Wigand.  Pitfalls in the identification of adenoviruses. , 1987, Journal of virological methods.

[16]  C. G. Loosli,et al.  Neutralizing and complement fixing antibody response to adenovirus infection. , 1956, The Journal of infectious diseases.

[17]  John O. Konz,et al.  Production and formulation of adenovirus vectors. , 2005, Advances in biochemical engineering/biotechnology.